Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News AHA 2023

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

Shelley Wood

November 14, 2023

Presentation AHA 2023

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Presenter: Alexander C. Fanaroff

November 13, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Conference News AHA 2022

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

Shelley Wood

November 06, 2022

News Conference News AHA 2022

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

Michael O'Riordan

November 04, 2022

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

Todd Neale

November 15, 2021

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Conference News AHA 2020

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

Shelley Wood

November 14, 2020

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

News Conference News AHA 2019

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

Todd Neale

November 16, 2019

News Conference News AHA 2019

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Michael O'Riordan

November 14, 2019

News Opinion Off Script AHA 2019

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

Ajay Kirtane, MD, SM

November 12, 2019

News Conference News AHA 2019

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Shelley Wood

October 25, 2019

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Michael O'Riordan

November 12, 2017

Advertisement

Automatic Scripts, Pharmacist Phone Calls Boost Statin Prescribing

Two Randomized Controlled Trials of Nudges to Encourage Referrals to Centralized Pharmacy Services for Evidence-Based Statin Initiation in High-Risk Patients: The SUPER LIPID Program

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI

High-Sensitivity Troponin Testing on the Rise in the US but Still Limited

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

OCT and MRI Find an MI Cause in 85% of Women With MINOCA: HARP

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

ISCHEMIA-CKD: Routine Invasive Approach No Help in CKD Patients With Stable CAD

More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA

Off Script: Will ISCHEMIA Answer Our Most Pressing Questions?

ISCHEMIA Countdown Begins, but a ‘Black-and-White’ Answer Is Uncertain

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Circling Back on ORBITA: Sham-Controlled PCI Trial Makes Best of 2017 List

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content